Jay S. Steingrub, MD, FACP

Department of Medicine
Division of Critical Care Medicine

• Professor of Medicine and Surgery, Tufts University School of Medicine

Baystate Critical Care Medicine
759 Chestnut Street
Springfield, MA 01199
v 413.794.5439
f  413.794.5389

email Jay.Steingrub@bhs.org

Fellowship

• Critical Care
  University Health Center of  Pittsburgh

Residency

• Internal Medicine
  Rochester General Hospital
  University of Rochester School of Medicine and Dentistry               

Medical School

• State University of New York at Syracuse College of Medicine

• University of Rochester

• University Health Center of Pittsburgh

Professional Service

• Best Doctors in America, Inc.

• Reviewer - Journal Intensive Care Medicine

• Reviewer - Critical Care Medicine

• Reviewer – American Journal of Medicine

• Reviewer – Critical Care Forum

• Editorial Board Board - CHEST

• Reviewer- Journal of Postgraduate Medicine

Board Certification

• American Board of Internal Medicine

• Specialty Board of Critical Care Medicine

Areas of Interest

• Cytokine Levels in Septic Hearts

• Cardiac Performance in Shock States

• Respiratory Failure

• Multi-Organ System Failure

Selected Publications

• Steingrub JS, Tidswell MA, Higgins, TH:  Hemodynamic consequences of heart-lung interactions.  J Int Care Med 2003;18(2):92-99.

• Lopez A, Lorente JA, Steingrub JS et al:  A multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88:  Effect on survival in patients with septic shock (study no. LMAB3001) .  Crit Care Med 2004;32(1):21-30.
  

• Steingrub JS:  Pregnancy associated severe liver dysfunction.  Critical Care Clinics 2004;20(4):763-776.
  

• Levy H, Small D, Heiselman, DE, Riker R, Steingrub JS et al:  Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis.  Ann Pharmacother 2005;39:
  

• Higgins TL, Steingrub JS, Tidswell MA, Tereso G, McGee WT:  Recombinant human activated Protein C in sepsis:  Initial experience with patient selection, cost and clinical outcomes.  J Inten Care Med 2005.  In Press
  

• Wheeler A, Steingrub J, Schmidt E et al:  A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis:  Comparison to a controlled clinical trial.  Crit Care Med 2005.  In press.
  

• Zeiher B, Steingrub JS, Lateere P-F et al:  LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outco
  me in patients with severe sepsis.  Crit Care Med 2005;33:1741-1748.

• Guntupalli SR and Steingrub JS:  Hepatic disease and pregnancy:  An overview of diagnosis and management.  Crit Care Med 2005;33(Suppl):S332-S339.

• Vincent J-L, Bernard GR, Beale R et al for the ENHANCE Study Group (Co-Investigator Steingrub JS):  Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE:  Further evidence for survival and safety and implications for early treatment.  Crit Care Med 2005;33(10):2266-2277.
  

• Higgins TL, Steingrub JS, Tereso, GJ, Tidswell MA, McGee WT:  Drotrecogin alfa (activated) in sepsis:  Initial experience with patient selection, cost, and clinical outcomes.  J Inten Care Med 2005;20:339-345.
  

• The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trails Network (Steingrub JS):  Pulmonary-Artery versus central venous catheter to guide treatment of acute lung injury.  N Engl J Med 2006;354:2213-2224.
  

• The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trails Network (Steingrub JS):  Comparison of two fluid-management strategies in acute lung injury.  N Engl J Med 2006;354:1-12.
  

• Steingrub JS:  Adding Up the Zeros (ALI/ARDS treatment).  J Inten Care Med 2006;21:188-190.